Future Developments: Engineering the Neurotoxin

Understanding the structure and molecular basis of neurotoxin function has opened up opportunities to engineer novel therapeutic proteins that utilise the neurotoxins and neurotoxin domains. These opportunities and the status of their de- velopment are reviewed in this chapter, which brings together the findings detailed in the companion volume to this book, KA Foster (ed) Molecular Aspects of Bo- tulinum Neurotoxin, Springer, New York, and shows how they can be applied for the development of innovative therapeutics and research tools.

[1]  A. Dickenson,et al.  Inhibition of Release of Neurotransmitters from Rat Dorsal Root Ganglia by a Novel Conjugate of a Clostridium botulinumToxin A Endopeptidase Fragment and Erythrina cristagalliLectin* , 2002, The Journal of Biological Chemistry.

[2]  C. Quinn,et al.  Inhibition of Vesicular Secretion in Both Neuronal and Nonneuronal Cells by a Retargeted Endopeptidase Derivative ofClostridium botulinum Neurotoxin Type A , 2000, Infection and Immunity.

[3]  G. Ahnert-Hilger,et al.  Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates , 2004, Journal of neurochemistry.

[4]  J. Navaza,et al.  Domain organization in Clostridium botulinum neurotoxin type E is unique: its implication in faster translocation. , 2008, Journal of molecular biology.

[5]  N. Fairweather,et al.  A Multi-domain Protein System Based on the HC Fragment of Tetanus Toxin for Targeting DNA to Neuronal Cells , 2003, Journal of drug targeting.

[6]  P. Hüppi,et al.  A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. , 2012, The Journal of clinical investigation.

[7]  H. Bigalke,et al.  Exchange of the HCC domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin , 2011, The FEBS journal.

[8]  J. Dolly,et al.  Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators , 2011, The FEBS journal.

[9]  H. Bigalke,et al.  The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction , 2003, Molecular microbiology.

[10]  K. Janda,et al.  Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1 , 2011, FEBS letters.

[11]  D. Finn,et al.  A Dileucine in the Protease of Botulinum Toxin A Underlies Its Long-lived Neuroparalysis , 2010, The Journal of Biological Chemistry.

[12]  K Ravi Acharya,et al.  Engineering toxins for 21st century therapies , 2011, The FEBS journal.

[13]  C. John,et al.  Targeted secretion inhibitors-innovative protein therapeutics. , 2010, Toxins.

[14]  M. Bodeker,et al.  Novel Chimeras of Botulinum Neurotoxins A and E Unveil Contributions from the Binding, Translocation, and Protease Domains to Their Functional Characteristics* , 2008, Journal of Biological Chemistry.

[15]  K. Acharya,et al.  Crystal structure of a catalytically active, non-toxic endopeptidase derivative of Clostridium botulinum toxin A. , 2009, Biochemical and biophysical research communications.

[16]  Anthony Scott-Tucker,et al.  Preparation of specifically activatable endopeptidase derivatives of Clostridium botulinum toxins type A, B, and C and their applications. , 2005, Protein expression and purification.

[17]  B. Davletov,et al.  SNARE tagging allows stepwise assembly of a multimodular medicinal toxin , 2010, Proceedings of the National Academy of Sciences.

[18]  A. Dickenson,et al.  Retargeted clostridial endopeptidases: Inhibition of nociceptive neurotransmitter release in vitro, and antinociceptive activity in in vivo models of pain , 2002, Movement disorders : official journal of the Movement Disorder Society.

[19]  S. Swaminathan,et al.  Crystallization and preliminary X-ray analysis of Clostridium botulinum neurotoxin type B. , 2000, Acta crystallographica. Section D, Biological crystallography.

[20]  A. T. Carter,et al.  Independent evolution of neurotoxin and flagellar genetic loci in proteolytic Clostridium botulinum , 2009, BMC Genomics.

[21]  Eric A. Johnson,et al.  Catalytic properties of botulinum neurotoxin subtypes A3 and A4. , 2009, Biochemistry.

[22]  A. B. Scott,et al.  Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. , 1980, Ophthalmology.

[23]  R. Stevens,et al.  Crystal structure of botulinum neurotoxin type A and implications for toxicity , 1998, Nature Structural Biology.

[24]  G. Oyler,et al.  Accelerated Neuronal Cell Recovery from Botulinum Neurotoxin Intoxication by Targeted Ubiquitination , 2011, PloS one.

[25]  K. Acharya,et al.  Structure and activity of a functional derivative of Clostridium botulinum neurotoxin B. , 2011, Journal of structural biology.

[26]  C. Quinn,et al.  Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A. , 2002, Protein expression and purification.

[27]  A. Pickett,et al.  Towards New Uses of Botulinum Toxin as a Novel Therapeutic Tool , 2011, Toxins.

[28]  U. Weller,et al.  Cooperative action of the light chain of tetanus toxin and the heavy chain of botulinum toxin type A on the transmitter release of mammalian motor endplates , 1991, Neuroscience Letters.

[29]  J. Barbieri,et al.  Engineering botulinum neurotoxin to extend therapeutic intervention , 2009, Proceedings of the National Academy of Sciences.

[30]  E. Maywood,et al.  Re-Assembled Botulinum Neurotoxin Inhibits CNS Functions without Systemic Toxicity , 2011, Toxins.

[31]  C. Quinn,et al.  A Conjugate Composed of Nerve Growth Factor Coupled to a Non-toxic Derivative of Clostridium botulinum Neurotoxin Type A can Inhibit Neurotransmitter Release in Vitro , 2000, Growth factors.

[32]  D. Rogers,et al.  Re-engineering the target specificity of clostridial neurotoxins - a route to novel therapeutics , 2006, Neurotoxicity Research.

[33]  M. Jackson,et al.  Syntaxin requirement for Ca2+-triggered exocytosis in neurons and endocrine cells demonstrated with an engineered neurotoxin. , 2011, Biochemistry.

[34]  Frank J Erbguth,et al.  Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin , 2004, Movement disorders : official journal of the Movement Disorder Society.